facebook-pixel

FDA panel endorses Pfizer booster for elderly or high-risk individuals

The FDA has the final word on vaccine approvals, and although it’s not obliged to follow the committee’s recommendations, it typically does.

(Saul Martinez | The New York Times) People register at a COVID-19 vaccination event in Miami on Aug. 5, 2021. The Food and Drug Administration’s independent panel of vaccine advisers is meeting Friday, Sept. 17, 2021, to discuss the case for booster shots of the Pfizer-BioNTech coronavirus vaccine, and to vote on whether the agency should approve additional doses for people 16 and older.

(Saul Martinez | The New York Times) People register at a COVID-19 vaccination event in Miami on Aug. 5, 2021. The Food and Drug Administration’s independent panel of vaccine advisers is meeting Friday, Sept. 17, 2021, to discuss the case for booster shots of the Pfizer-BioNTech coronavirus vaccine, and to vote on whether the agency should approve additional doses for people 16 and older.

MOST VIEWED

By Sharon LaFraniere and Noah Weiland | The New York Times